Table 1. Biological activities and physicochemical properties of series 4 and 5.
![]() | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|
| ||||||||||
GI50 (μM)b | Propertiesc | |||||||||
|
|
|||||||||
R1 | R3 | IC50 (μM)a Mer TK | A549 | KB | KB-vin | DU145 | MV4-11 | Aq Sol (μg/mL) | Log P | |
4a |
![]() |
H | 1.08 | 10.1 | 11.1 | 12.6 | 12.4 | 4.91 | 10.4 | >5 |
5a |
![]() |
Me | 1.14 | 9.4 | 11.7 | 10.1 | 10.2 | 2.70 | 1.11 | >5 |
4b |
![]() |
H | 0.68 | 15.2 | 20.3 | 17.1 | 18.3 | 8.75 | 95.6 | 2.54 |
5b |
![]() |
Me | 2.01 | 13.0 | 24.8 | 30.8 | 30.2 | 70.1 | ND | ND |
4c |
![]() |
H | 3.43 | 3.53 | 5.33 | 5.09 | 4.08 | 5.88 | 4.36 | >5 |
5c |
![]() |
Me | 1.84 | 12.4 | 13.7 | 12.4 | 13.0 | 2.33e | 3.43 | >5 |
4d |
![]() |
H | 2.25 | 16.1 | 14.8 | 17.5 | 14.3 | 3.07 | 6.61 | 3.21 |
5d |
![]() |
Me | 10.2 | 19.9 | 18.7 | 22.9 | 24.3 | ND | ND | ND |
4e |
![]() |
H | 2.06 | 20.1 | 21.0 | 15.3 | 20.1 | ND | ND | ND |
5e |
![]() |
Me | >30 | NDd | ND | ND | ND | ND | ND | ND |
4f |
![]() |
H | 3.56 | 13.0 | 13.3 | 13.4 | 13.0 | <13.4 | ND | ND |
5g |
![]() |
Me | >30 | ND | ND | ND | ND | ND | ND | ND |
Staurosporinef | 0.00081 | |||||||||
Paclitaxel (nM)f | 4.9 | 2.6 | 948 | 2.6 | ND |
The concentration that inhibits 50% Mer tyrosine kinase.
The concentration inhibits 50% human tumor cell growth, averaged values determined by at least three independent experiments.
Active compounds with IC50 < 10 μM and GI50 < 20 μM were measured by the methods in Ref. 19.
Not detected.
Tested in human chronic myelogenous leukemia (K526) cells.
Reference compounds as the positive control in related assays.